RxDoctor Payments Data

Coreen Huo, DO

Nephrology · Glendale, CANPI 1932626553

Payments from drug & device makers

$3,565in general payments, 2019–2025

Across 109 payments — averaging $32.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$898
  • Aurinia Pharma U.S., Inc.$734
  • Akebia Therapeutics Inc$371
  • Bayer$359
  • Amgen$257
  • Otsuka America Pharmaceutical, Inc.$198
  • plus $749 from 10 others

What the payments were for

  • Food & beverage$3,25991%
  • Education$3079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,565 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$357,151
Medicare patients
518
Services billed
2,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide38$104,436
JardianceEmpagliflozin90$80,769
ProcritEpoetin Alfa20$52,009
VeltassaPatiromer Calcium Sorbitex41$43,540
Sevelamer Hcl16$34,860
LokelmaSodium Zirconium Cyclosilicate40$33,126
FarxigaDapagliflozin Propanediol45$32,086
Cinacalcet Hcl11$15,861
DapagliflozinDapagliflozin Propanediol30$15,622
KerendiaFinerenone17$10,902
Sevelamer Carbonate31$4,296
Calcium Acetate34$2,966
Nifedipine ErNifedipine20$1,202
Losartan Potassium92$1,136
Metolazone11$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$80,76990 claims
AstraZenecaLokelma, Farxiga$898$65,21385 claims
Johnson & JohnsonProcrit$142$52,00920 claims
BayerKerendia$359$10,90217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.

Other nephrology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →